PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.54%
Revenue growth above 1.5x CSIQ's 2.02%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-0.76%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-91.91%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
76.66%
Operating income growth 1.25-1.5x CSIQ's 53.11%. Bruce Berkowitz would see if strategic measures (e.g., cost cutting, product mix) are succeeding.
-94.39%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-94.87%
Negative EPS growth while CSIQ is at 8.04%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-94.44%
Negative diluted EPS growth while CSIQ is at 0.91%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.06%
Slight or no buybacks while CSIQ is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-8.82%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
-119.63%
Negative OCF growth while CSIQ is at 475.97%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-13.53%
Negative FCF growth while CSIQ is at 322.03%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
-50.04%
Negative 10Y revenue/share CAGR while CSIQ stands at 348.21%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-39.49%
Negative 5Y CAGR while CSIQ stands at 61.23%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-27.93%
Negative 3Y CAGR while CSIQ stands at 98.89%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-105.61%
Negative 10Y OCF/share CAGR while CSIQ stands at 485.45%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-119.42%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-341.68%
Negative 3Y OCF/share CAGR while CSIQ stands at 188.68%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
103.58%
Net income/share CAGR at 50-75% of CSIQ's 149.69%. Martin Whitman might question if the firm’s product or cost base lags behind.
101.07%
5Y net income/share CAGR above 1.5x CSIQ's 14.93%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
22.42%
3Y net income/share CAGR above 1.5x CSIQ's 6.61%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-60.55%
Negative equity/share CAGR over 10 years while CSIQ stands at 347.38%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
222.10%
5Y equity/share CAGR above 1.5x CSIQ's 70.55%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
4848.85%
3Y equity/share CAGR above 1.5x CSIQ's 29.31%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y dividend/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
5.03%
AR growth well above CSIQ's 3.60%. Michael Burry fears inflated revenue or higher default risk in the near future.
38.80%
We show growth while CSIQ is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
3.64%
Asset growth at 75-90% of CSIQ's 4.34%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
1.53%
Under 50% of CSIQ's 18.37%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
1.70%
Debt growth far above CSIQ's 0.79%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-18.04%
Our R&D shrinks while CSIQ invests at 15.22%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-5.70%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.